The Hill: Sen. Bernie Sanders (I-Vt.) on Monday asked a pharmaceutical company why a drug that was once free for patients now costs as much as $375,000 annually.
Catalyst Pharmaceuticals informed investors in December about the new pricing for Firdapse, which is used to treated the rare neuromuscular disorder Lambert-Eaton Myasthenic Syndrome (LEMS), Sanders wrote in a letter to the company.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now